Analysts Set Envista Holdings Co. (NYSE:NVST) Price Target at $20.65

Shares of Envista Holdings Co. (NYSE:NVST) have earned an average rating of “Hold” from the sixteen analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.65.

A number of equities analysts have recently commented on NVST shares. Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, October 31st. Leerink Partners raised shares of Envista from an “underperform” rating to a “market perform” rating and increased their target price for the stock from $16.00 to $23.00 in a report on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Envista in a research note on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price target on the stock. Piper Sandler upped their price objective on shares of Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Finally, Evercore ISI increased their price objective on shares of Envista from $18.00 to $23.00 and gave the company an “outperform” rating in a research note on Monday, September 23rd.

Institutional Investors Weigh In On Envista

Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Envista in the third quarter valued at approximately $31,000. GAMMA Investing LLC lifted its holdings in shares of Envista by 69.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after purchasing an additional 726 shares in the last quarter. Huntington National Bank grew its position in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after purchasing an additional 949 shares during the period. Blue Trust Inc. increased its stake in Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after buying an additional 728 shares during the last quarter.

Envista Stock Up 0.9 %

Shares of NVST opened at $19.29 on Monday. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. Envista has a 12 month low of $15.15 and a 12 month high of $25.64. The firm’s 50 day moving average is $20.25 and its 200-day moving average is $18.48. The stock has a market capitalization of $3.32 billion, a PE ratio of -2.48, a P/E/G ratio of 2.71 and a beta of 1.31.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. The company had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. Envista’s quarterly revenue was down 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 EPS. Equities research analysts forecast that Envista will post 0.72 EPS for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.